BioSpace News Archive

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.

Mural Oncology plc announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

InspireMD, Inc. announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course 2024, which is being held May 28-31, in Leipzig, Germany.

Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024.

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM).

Opus Genetics today announced that the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).

Portage Biotech Inc. reported that it has completed selling its equity holding in Intensity Therapeutics.

Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open.

TiumBio Co., Ltd. (Kosdaq: 321550) has announced the filing of a Clinical Trial Application (CTA) with the Italian Medicines Agency (AIFA) and the Spanish Agency of Medicines and Medical Products (AEMPS) to initiate a Phase 1b study of TU7710, a novel recombinant activated factor VII (rFVIIa) for hemophilia patients with inhibitors.